Eli Lilly and Company (NYSE:LLY) Stock Price Up 2.5% – Should You Buy?

13 May 2026, 18:00 by Renee Jackson · The Cerbat Gem

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) were up 2.5% during trading on Wednesday . The company traded as high as $1,022.82 and last traded at $1,014.9290. Approximately 3,466,683 shares changed hands during mid-day trading, an increase of 8% from the average daily volume of 3,210,025 shares. The stock had previously closed at $989.87.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: New late-stage trial results showed patients largely maintained weight loss after switching to Foundayo or lower-dose Zepbound, strengthening confidence in Lilly’s obesity franchise and its ability to extend the life of its GLP-1 portfolio. Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss
Positive Sentiment: Lilly is also highlighting next-generation obesity candidates, including oral pills and retatrutide, which signals a broader pipeline strategy to stay ahead of rivals in the rapidly growing weight-loss market. Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
Positive Sentiment: Analysts continue to frame Lilly as a dominant GLP-1 winner, with coverage noting the company is cementing its lead in the massive obesity drug market. GLP-1 Wars: Winners & Losers
Neutral Sentiment: The company launched its Alzheimer’s drug in India and marked its 150th anniversary with community and manufacturing announcements, which are positive for long-term strategy but likely less important for near-term trading. Eli Lilly launches Alzheimer’s drug Donanemab in India
Negative Sentiment: Rising competition remains a watch item, as a new obesity-focused challenger, Kailera Therapeutics, is drawing analyst attention and could eventually pressure Lilly’s market dominance if its pipeline develops successfully. This Weight-Loss Drug Challenger Could Follow Eli Lilly’s Playbook: Analyst

Analyst Ratings Changes

Several research analysts recently commented on LLY shares. Royal Bank Of Canada reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, May 1st. Daiwa Securities Group upped their price target on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Wolfe Research reiterated an “outperform” rating and set a $1,325.00 price objective on shares of Eli Lilly and Company in a research note on Monday, May 4th. The Goldman Sachs Group boosted their target price on shares of Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. Finally, Scotiabank reaffirmed an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,218.33.

Get Our Latest Report on Eli Lilly and Company

Eli Lilly and Company Trading Up 2.5%

The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock has a market cap of $955.80 billion, a P/E ratio of 36.05, a PEG ratio of 1.05 and a beta of 0.48. The firm’s 50-day simple moving average is $939.93 and its 200 day simple moving average is $994.31.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s payout ratio is 24.58%.

Institutional Investors Weigh In On Eli Lilly and Company

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Eli Lilly and Company by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after buying an additional 1,006,885 shares in the last quarter. State Street Corp boosted its holdings in shares of Eli Lilly and Company by 1.8% in the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock valued at $38,002,744,000 after acquiring an additional 635,358 shares in the last quarter. Capital Research Global Investors increased its stake in shares of Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after acquiring an additional 4,332,008 shares during the period. Morgan Stanley increased its stake in shares of Eli Lilly and Company by 2.7% during the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after acquiring an additional 407,166 shares during the period. Finally, Capital World Investors raised its holdings in Eli Lilly and Company by 0.4% during the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after purchasing an additional 61,851 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.